Yu, D ORCID: 0000-0002-8449-7725 (2015) Association between lung capacity and abnormal glucose metabolism: Findings from China and Australia. Clinical Endocrinology, 85 (1). pp. 37-45. ISSN 1365-2265

[img]
Preview
Text
D Yu - Association between lung capacity and abnormal glucose metabolism - Findings from China and Australia.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial.

Download (701kB) | Preview

Abstract

Objective
Restricted pulmonary function is found among people with diabetes. This study aimed to investigate the dose–response relationship between pulmonary function measurements [forced expiratory volume in one second (FEV1) and forced vital capacity (FVC)] and risk of metabolic syndrome (MS)/type 2 diabetes.

Methods
A total of 1454 adults in rural Victoria, Australia, and 5824 adults in Nanjing, China, from randomly selected households provided clinical history, oral glucose tolerance test, lipids, anthropometric, blood pressure and spirometric measurements. MS was defined by International Diabetes Federation criteria. Adjusted odds ratios for MS and type 2 diabetes with lung capacity measurements were estimated using logistic regression. Dose–response relationships were explored using the restricted cubic spline models.

Results
There was a nonlinear relationship between FEV1 and the risk of type 2 diabetes and MS (both P < 0·0001) in both the Australian and Chinese populations. The FEV1 associated with the lowest risk of type 2 diabetes and MS was above 2·70 l (95%CI: 2·68 to 2·72 l and 2·65 to 2·76 l in Chinese and Australian populations, respectively). The discrimination of the model could be significantly improved using the FEV1 threshold in both the Australian and Chinese populations.

Conclusions
In both the Australian and Chinese populations, the risk of type 2 diabetes and MS is lowest with a FEV1 of 2·65–2·76 l. This might be used in clinical practice in different countries as a prompt to screen for type 2 diabetes and MS in patients with obstructive lung disease and to ensure there was no abnormal glucose metabolism before the commencement of steroids if indicated.

Item Type: Article
Additional Information: This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Wiley at https://doi.org/10.1111/cen.13006 Please refer to any applicable terms of use of the publisher.
Subjects: R Medicine > RA Public aspects of medicine
Divisions: Faculty of Medicine and Health Sciences > Primary Care Health Sciences
Depositing User: Symplectic
Date Deposited: 08 Feb 2016 16:15
Last Modified: 06 Jul 2018 13:33
URI: http://eprints.keele.ac.uk/id/eprint/1398

Actions (login required)

View Item View Item